Engineering an IL2-Free, Potent & Persistent TIL With Regulated Membrane-Bound IL15

Time: 12:30 pm
day: Day Two


• Sidestepping capillary leak syndrome associated toxicity and Treg effects

• Removing the need for toxic and costly IL2 therapy associated with conventional TILs

• Uncovering clinical potential as a novel TIL product with enhanced safety and efficacy